Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Luu

Cardiovascular Disease Pasadena, CA Medical Doctor

NPI 1578520763 CMS profile 778406

625 S Fair Oaks Ave, Suite 215, Pasadena, CA 91105

Open in the dashboard

General payments

$6,239

285 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Luu of Pasadena, CA is reported in the CMS Open Payments database as having received $6,239 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $648 26
2024 General $414 23
2023 General $811 32
2022 General $1,080 53
2021 General $985 47
2020 General $755 26
2019 General $1,546 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Luu
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Michael Luu were reported at $648. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Michael Luu Cardiovascular Disease median Middle half National median
2019 $1,546 $450 $127–$1,392 $163
2020 $755 $242 $77–$751 $114
2021 $985 $335 $101–$1,037 $132
2022 $1,080 $395 $121–$1,211 $149
2023 $811 $443 $136–$1,283 $160
2024 $414 $450 $136–$1,323 $164
2025 $648 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,371 79 payments
  2. Pfizer Inc. $802 45 payments
  3. Amgen Inc. $797 38 payments
  4. Actelion Pharmaceuticals US, Inc. $704 29 payments
  5. Boston Scientific Corporation $566 10 payments
  6. Abbott Laboratories $249 10 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $191 13 payments
  8. E.R. Squibb & Sons, L.L.C. $161 10 payments
  9. Medtronic Vascular, Inc. $144 1 payment
  10. Ortho Dermatologics, a division of Bausch Health US, LLC $143 1 payment
  11. Other $1,111 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,239 285 payments
Products named General payments · program years 2019–2025
  1. Repatha $777 37 payments
  2. UPTRAVI $704 29 payments
  3. OPSUMIT $704 29 payments
  4. ENTRESTO $698 44 payments
  5. VYNDAQEL $484 27 payments
  6. LEQVIO Cardiology/Vascular Diseases $446 24 payments
  7. Corlanor $350 19 payments
  8. ELIQUIS $322 18 payments
  9. LEQVIO Cardiovascular $297 16 payments
  10. LifeVest $191 13 payments
  11. Other $3,023 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

3,702

Median for Cardiology: 2,533

Drug cost

$918,211

Median for Cardiology: $485,213

Branded share of claims

28.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 350 $348,358
Entresto Sacubitril/Valsartan Brand 313 $308,399
Jardiance Empagliflozin Brand 127 $105,755
Xarelto Rivaroxaban Brand 74 $67,427
Repatha Sureclick Evolocumab Brand 27 $30,768
Rosuvastatin Calcium Generic 658 $10,064
Brilinta Ticagrelor Brand 12 $7,912
Praluent Pen Alirocumab Brand 13 $6,125
Amiodarone Hcl Generic 161 $6,019
Ranolazine Er Ranolazine Brand 21 $3,385

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$157,768

Medicare's payments for the services billed

Medicare patients

799

Average age 77

Services billed

1,952

367 women, 432 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 50%
Diabetes 37%
Atrial fibrillation 30%
Chronic kidney disease 27%
Heart failure 26%
Cancer 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
  • PFIZER INC. $118
$118 — —
Repatha
  • Amgen Inc. $41
$41 27 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $36
$36 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $36
$36 313 —
NEXLETOL
  • Esperion Therapeutics, Inc. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record